Abstract
To explore apolipoprotein E gene variants distribution among the patients of Alzheimer’s disease and vascular dementia for the elderly community population in Nanking, the polymerase chain reaction and restriction fragment length polymorphism techniques were employed to analyze the gene frequency of apolipoprotein E (ApoE) for 113 cases with Alzheimer’s disease (AD), 85 cases with vascular dementia (VaD), 147 cases with questionable dementia (QD), and 396 dementia-free controls. It was found that ApoE ε4 gene container (37.17%) and allele frequency (21.24±2.72) of ApoE ε4 in AD group were significantly higher than those in both control and VaD group (p<0.05). With the increment of ε4 gene dose, the incidence of the AD was significantly increased. Compared with the control group, ApoE ε4 had risk ratio (RR) of 1.82 to develop AD (p =4e-4), and attributable risk percentage (ARP) of 45%. These results suggest that ApoE ε4 gene may be responsible for up to 45% of the genetic component of Alzheimer’s disease, and may act as a discriminator between AD and VaD as well.
Keywords: Alzheimer’s disease, vascular dementia, apolipoprotein E.
Medicinal Chemistry
Title:Apolipoprotein E Gene Variants of Alzheimer's Disease and Vascular Dementia Patients in a Community Population of Nanking
Volume: 10 Issue: 8
Author(s): Wen-Zheng Chu, Li Gong, Ying-Qiu Xu, Guo-Hua Cai and Kuo-Chen Chou
Affiliation:
Keywords: Alzheimer’s disease, vascular dementia, apolipoprotein E.
Abstract: To explore apolipoprotein E gene variants distribution among the patients of Alzheimer’s disease and vascular dementia for the elderly community population in Nanking, the polymerase chain reaction and restriction fragment length polymorphism techniques were employed to analyze the gene frequency of apolipoprotein E (ApoE) for 113 cases with Alzheimer’s disease (AD), 85 cases with vascular dementia (VaD), 147 cases with questionable dementia (QD), and 396 dementia-free controls. It was found that ApoE ε4 gene container (37.17%) and allele frequency (21.24±2.72) of ApoE ε4 in AD group were significantly higher than those in both control and VaD group (p<0.05). With the increment of ε4 gene dose, the incidence of the AD was significantly increased. Compared with the control group, ApoE ε4 had risk ratio (RR) of 1.82 to develop AD (p =4e-4), and attributable risk percentage (ARP) of 45%. These results suggest that ApoE ε4 gene may be responsible for up to 45% of the genetic component of Alzheimer’s disease, and may act as a discriminator between AD and VaD as well.
Export Options
About this article
Cite this article as:
Chu Wen-Zheng, Gong Li, Xu Ying-Qiu, Cai Guo-Hua and Chou Kuo-Chen, Apolipoprotein E Gene Variants of Alzheimer's Disease and Vascular Dementia Patients in a Community Population of Nanking, Medicinal Chemistry 2014; 10 (8) . https://dx.doi.org/10.2174/1573406410666140327120714
DOI https://dx.doi.org/10.2174/1573406410666140327120714 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Animal Models for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Clinical, Immunological and Therapeutic Aspects of Autoimmune Encephalitis
Recent Patents on CNS Drug Discovery (Discontinued) NMDA Receptor Antagonists: Repositioning of Memantine as a Multitargeting Agent for Alzheimer's Therapy
Current Pharmaceutical Design From Physiome to Pathome: A Systems Biology Model of Major Depressive Disorder and the Psycho-Immune-Neuroendocrine Network
Current Psychiatry Reviews Current Development of ROS-Modulating Agents as Novel Antitumor Therapy
Current Cancer Drug Targets Processing of Amyloid Precursor Protein as a Biochemical Link Between Atherosclerosis and Alzheimers Disease
Cardiovascular & Hematological Disorders-Drug Targets The Role of Saffron in Attenuating Age-related Oxidative Damage in Rat Hippocampus
Recent Patents on Food, Nutrition & Agriculture Lifestyle and Genetic Contributions to Cognitive Decline and Hippocampal Structure and Function in Healthy Aging
Current Alzheimer Research Dopaminergic Enhancement of Cognitive Function
Current Pharmaceutical Design Relationship Between the Chemokine Receptor CCR5 and Microglia in Neurological Disorders: Consequences of Targeting CCR5 on Neuroinflammation, Neuronal Death and Regeneration in a Model of Epilepsy
CNS & Neurological Disorders - Drug Targets Treatment of Large Vessel Vasculitis
Current Immunology Reviews (Discontinued) [<sup>18</sup>F]-florbetaben PET/CT Imaging in the Alzheimer’s Disease Mouse Model APPswe/PS1dE9
Current Alzheimer Research Review on Plants with Traditional Uses and Bio-activity against Hair Graying
Current Traditional Medicine Apoptosis and Acute Brain Ischemia in Ischemic Stroke
Current Vascular Pharmacology In-silico Design, ADMET Screening, Prime MM-GBSA Binding Free Energy Calculation and MD Simulation of Some Novel Phenothiazines as 5HT6R Antagonists Targeting Alzheimer’s Disease
Current Computer-Aided Drug Design Functional Activities Questionnaire Items that Best Discriminate and Predict Progression from Clinically Normal to Mild Cognitive Impairment
Current Alzheimer Research Dynamic Role of Macrophage Sub Types on Development of Atherosclerosis and Potential Use of Herbal Immunomodulators as Imminent Therapeutic Strategy
Cardiovascular & Hematological Agents in Medicinal Chemistry Alzheimers Disease-Associated Neurotoxic Mechanisms and Neuroprotective Strategies
Current Drug Targets - CNS & Neurological Disorders Co-ultraPEALut: Role in Preclinical and Clinical Delirium Manifestations
CNS & Neurological Disorders - Drug Targets Nutrient-By-Genotype Interactions and Personalized Diet: What Can We Learn From Drosophila and Evolutionary Biology?
Current Pharmacogenomics and Personalized Medicine